SML3925

Liraglutide

≥95% (HPLC), GLP-1 receptor agonist, Powder or Lyophilized powder or film

• Synonym(e): Arg34, Lys26-[Nε(γ-Glu[Nα-hexadecanoyl])]-GLP-1[7-37], H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-N6-[N-(1-oxohexadecyl)-L-γ-glutamyl]-Lys-α-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH, HAEGTFTSDVSSYLEGQAA-N6-[N-(1-oxohexadecyl)-L-γ-glutamyl]K-EFIAWLVRGRG, NN2211
• Empirische Formel (Hill-System): C₁₇₂H₂₆₅N₄₃O₅₁
• CAS-Nummer: 204656-20-2
• Molekulargewicht: 3751.20
• UNSPSC Code: 51111800
• NACRES: NA.77
• Assay: ≥95% (HPLC)
• Form: (Powder or Lyophilized powder or film)

Eigenschaften

• Produktname: Liraglutide, ≥95% (HPLC)
• Quality Segment: 100
• assay: ≥95% (HPLC)
• form: (Powder or Lyophilized powder or film)
• color: white to off-white
• storage temp.: -10 to -25°C

Beschreibung

Biochem/physiol Actions

Glucagon-like peptide-1 (GLP-1)-based incretin mimetic with enhanced in vivo stability and efficacy against type 2 diabetes and obesity.

Liraglutide (NN2211) is a glucagon-like peptide-1 (GLP-1)-based incretin mimetic (cAMP stimulation EC50 = 61 nM vs 55 nM with GLP-1(7-37) using human GLP-1 receptor-expressing BHK cells), where GLP-1(7-37) sequence is modified with a Lys34-to-Arg substitution and a γ-Glu-C16 acylation on Lys26 for enhanced in vivo stability (plasma t1/2 in pigs post s.c. = 14 h vs 1.2 h with GLP-1(7-37)) and efficacy against type 2 diabetes and obesity (400 μg/kg/day s.c. in rats; 100-200 μg/kg bid or single 50-200 μg/kg i.v. in rats; 100 μg/kg bid or single 30-1000 μg/kg s.c. in mice; 2 μg/kg i.v. or 3.3 μg/kg/day s.c. in pigs).

Sicherheitshinweise

• Signalwort: Warning
• Lagerklasse: 11 - Combustible Solids
• Was ist los?: WGK 3
• Piktogramme: GHS08,GHS07
• Gefahrencodes: H302,H361d
• Sicherheitshinweise: P202 - P264 - P280 - P301 + P312 - P308 + P313 - P405
• Hazard Classifications: Acute Tox. 4 Oral - Repr. 2